Chad Landmon Image

Chad Landmon

is a partner at Axinn, Veltrop & Harkrider, LLP, where he Chairs the firm’s Intellectual Property and FDA Practice Groups and regularly works with companies developing drugs, biologics, and regenerative medicine and human tissue products.

For more information or to contact Chad, please visit his Firm Profile Page.

Recent Articles by Chad Landmon

U.S. Government Patent Enforcement: A Ripple or a Coming Tempest?

In most respects, the widely reported patent complaint recently filed against Gilead is perfectly ordinary. It was filed in the U.S. District Court for the District of Delaware, the most common venue for patent infringement lawsuits, and alleged that a pharmaceutical company’s drug sales infringed the plaintiff’s patents on uses of the sold drug. The defendant’s response has so far been similarly unexceptional:  Gilead has filed petitions for Inter Partes Review (IPR) of each asserted patent (see links below), arguing that those patents are invalid over the prior art, either as obvious or as entirely anticipated. What is remarkable about this lawsuit, however, is that the plaintiff is the government of the United States.